Zeneca Media News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RAIL Score Provides Useful, Noninvasive Biomarker for Renal Disease Activity

An analysis of data obtained from urine samples in the MUSE and TULIP-1 trial sheds new light on the clinical utility of the RAIL score for identifying disease activity and treatment responders in SLE patients with and without lupus nephritis, respectively

United statesHermine brunnerAstrazeneca media centreLongitudinal score associatesCincinnati childrenClinical rheumatologyHospital medical centerRenal activity indexIdentifies active renal diseaseRenal responsesReceptor monoclonal antibodyModerate to severe systemic lupusZeneca media

Anfirolumab-Treated Patients More Likely to Achieved Sustained Remission in SLE

Anfirolumab-Treated Patients More Likely to Achieved Sustained Remission in SLE
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

Astrazeneca media centreUniversity of amsterdam ronald van vollenhovenDrug administrationClinical rheumatologyActivity indexGlobal assessmentPost hoc analysisZeneca media

Anifrolumab-Treated Patients More Likely to Achieve Sustained Remission in SLE

Pooled data from the phase 3 TULIP program offer additional insight into the effects of anifrolumab use in people with moderate-to-severe systemic lupus erythematosus.

Astrazeneca media centreUniversity of amsterdam ronald van vollenhovenDrug administrationClinical rheumatologyActivity indexGlobal assessmentPost hoc analysisZeneca media